Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease.

MLA

Elstein, Deborah, et al. “Safety and Efficacy Results of Switch from Imiglucerase to Velaglucerase Alfa Treatment in Patients with Type 1 Gaucher Disease.” American Journal of Hematology, vol. 90, no. 7, July 2015, pp. 592–97. EBSCOhost, https://doi.org/10.1002/ajh.24007.

APA

Elstein, D., Mehta, A., Hughes, D. A., Giraldo, P., Charrow, J., Smith, L., Shankar, S. P., Hangartner, T. N., Kunes, Y., Wang, N., Crombez, E., & Zimran, A. (2015). Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease. American Journal of Hematology, 90(7), 592–597. https://doi.org/10.1002/ajh.24007

Chicago

Elstein, Deborah, Atul Mehta, Derralynn A. Hughes, Pilar Giraldo, Joel Charrow, Laurie Smith, Suma P. Shankar, et al. 2015. “Safety and Efficacy Results of Switch from Imiglucerase to Velaglucerase Alfa Treatment in Patients with Type 1 Gaucher Disease.” American Journal of Hematology 90 (7): 592–97. doi:10.1002/ajh.24007.